The use of heart rate in clinical practice is limited by its variability under measurement situations. The mean heart rate on ambulatory monitoring provides a more robust statistic for clinical use. We examined the relationship between mean heart rate on initial referral ambulatory blood pressure monitoring (ABPM) to the BP-lowering efficacy of the four main groups of antihypertensive medications, in a referral hypertensive population. Patients were retrospectively identified by review of the BP database, and data collected from the initial referral BP monitor off medication, and the subsequent ABPM after treatment with either beta-blockers, diuretics, calcium antagonists or angiotensin-converting enzyme (ACE) inhibitors. The change in mean
Introduction
The heart rate is one of the cardinal vital signs, and it has been well described in the normal population and in various pathological states. The primary drawback of reliance on heart rate as a disease indicator has been its great variability over short periods of time in response to external stresses. 1 The innate variability of the heart rate may be lessened by following the rate over a period of time, where instantaneous variation is hidden by the more robust statistical averaging of heart rate. Similar mechanisms have been used to more accurately determine the true blood pressure (BP) with the use of ambulatory blood pressure monitoring (ABPM).
Heart rate and BP are closely correlated, and hypertensive patients are known to have higher resting heart rates than normals. 2 The increased sympathetic nervous system tone would appear to be the causative element in this increase in heart rate along with a general increase in cardiac output and the production of a hyperkinetic circulation. 3 This pattern would appear to be most marked in younger hypertensives, 4 and it has been docu- arterial BP from the initial to the subsequent ABPM (ie, as a result of treatment) was correlated with the mean heart rate on the initial ABPM. A moderate association was found for initial daytime heart rate and BP response to beta-blockers (r = 0.24, P = 0.02), and ACE inhibitors (r = 0.14, P = 0.05). No such association was found for calcium antagonists or diuretics. When the groups were divided into those with a mean daytime heart rate Ͻ75 and у75 beats per min, BP reduction from beta-blocker and ACE inhibitor therapy was significantly greater in those patients with a higher daytime heart rate. We conclude that average daytime heart rate on pre-treatment ABPM can be useful as a predictor of BP response to beta-blockade or ACE inhibition.
mented that a high resting heart rate may in fact be predictive of future hypertension.
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The hypothesis we wished to test therefore was whether high mean heart rates as documented on ABPM were predictive of the likelihood of patients to respond to anti-hypertensive medications, in particular to direct sympathetic nervous system blockade with beta-blocker medication.
Patients and methods

Patient identification
Patients were identified from a retrospective search of the Blood Pressure Unit ambulatory BP database. Specifically, patients were selected if they had had an ambulatory BP monitor performed on no medications (which is a routine part of the assessment of patients referred for evaluation of BP in our unit), and had had a subsequent ambulatory BP monitor performed within 1 year of the first, after having been commenced on a single anti-hypertensive medication. The median length of time between each ABPM was 6 months (range 2-12). Patients were excluded if there was not a clear identification of medication history in the time period of the two monitors, if they had been commenced on combination anti-hypertensive medication, or had a coincident medical problem interfering with the estimation of heart rate (eg, atrial fibrillation, permanent pacemaker in situ), or likely to affect heart rate (eg, clinical heart failure). Patients with secondary hypertension, identified by a secondary hypertension screening protocol at the time of the first clinic visit, were not included in the study. Echocardiographic parameters of impaired left ventricular function, namely an ejection fraction of less than 40% or a dilated left ventricular cavity were identified from the patients records, and warranted the removal of the patients record from the analysis. The patients were prescribed the anti-hypertensive medication at their initial clinic visit, and the decision as to which medication to prescribe was clinically based, and was based on the ABPM measured pressure. Patients were grouped into groups on the basis of the drug they were prescribed at the first clinic visit, which they continued to take until the time of the second monitor. Specifically four drug classes were identified: diuretics; beta-blockers; angiotensin-converting enzyme inhibitors (ACEI); calcium channel blockers.
Ambulatory BP monitoring
Initial clinic BPs were measured by a trained nurse according to the British Hypertension Society BP measurement protocol. 6 ABPM was performed using a validated device. As the database was extended over 15 years, a variety of devices were used, which included the Remler-M2000, Accutracker I, SpaceLabs 5200, Tapeda TM-2420, SpaceLabs 90202, SpaceLabs 90207, NC-Diasys.200R, CH-Druck, Profilomat I and II, Nisser DS-240, and Schiller BR102. In practice, 89.4% of the first BP monitors and 93.8% of the subsequent monitors were either SpaceLabs 90202 or SpaceLabs 90207. The monitors were applied in accordance with the protocol for application of ambulatory BP monitors in our unit; the monitor was applied to the non-dominant arm between 9.00 am and noon, and the patient was instructed to carry on life as normal between readings but to have the arm rested at heart level during readings. The monitors were programmed to measure BP every half-hour, day and night. The data from the ambulatory BP monitor was downloaded the next day into a personal computer and uploaded into a specialised software package (DABLv™). The initial, daytime and night-time systolic diastolic and mean BP statistics and the mean daytime and nighttime heart rate was calculated. The 'initial' period was defined as the first 1 h of monitoring, and was considered apart from the daytime readings so as to exclude interference from white coat effects, 'daytime' was defined as the hours between 9.00 am and 9.00 pm, and night-time as the hours between 1.00 am and 6.00 am. These intervals are chosen in order to remove the influence of retiring and rising time fluctuations in the assessment of day and nighttime BP. Monitors were checked and downloaded the same day as the monitor was removed, and erroneous measurement values were not included in the statistical processing of the BP data.
Definitions
For the purposes of comparison, the heart rate was divided into three subsets; the initial heart rate (IHR), the average of the heart rate in the first 1 h of recording; the mean daytime heart rate (DHR), averaged over the daytime hours as defined above; and the mean night-time heart rate (NHR), averaged over the night-time hours as defined above. The BP data was calculated to give the mean daytime mean arterial pressure (MAP), and the mean night-time MAP. The BP response to anti-hypertensive therapy was calculated as the difference between mean daytime MAP and mean night-time MAP between the first and second monitors.
Statistical analysis
The following analyses were made. Firstly, the correlation between DHR and NHR on the initial ABPM and the BP response to anti-hypertensive medication was investigated using simple bivariate correlation. Then, in order to determine whether clinically identifiable heart rate bands existed where specific drug interventions were most useful, the patient population was divided into two groups according to diurnal heart rate on the initial ABPM; those with a DHR Ͻ75 bpm, and those with a DHR у75 bpm. Differences in anti-hypertensive drug efficacy between these groups were explored using Student's t-test. Differences between more than two groups were explored using analysis of variance, with probability adjustment using Bonferroni's method.
Results
A total of 437 suitable patients were identified. Mean age was 50.7 (CI 49.7-51.8). The population showed a mean BP at initial assessment (on no medication) of 117.3 (CI 116.3-118.3) mm Hg during the day, and 98.7 (CI 97.7-99.8) mm Hg at night of which 24.5% were subsequently prescribed diuretic monotherapy, 81% of whom received bendrofluazide with potassium supplementation, at a median dose of 5 mg per day. Other diuretics used were triamterene/hydrochlorothiazide (median dose 50 mg/25 mg), amilioride/hydrochlorothiazide (median dose 5 mg/50 mg), and frusemide/amilioride (median dose 40 mg/5 mg). Beta-blockers were prescribed to 22.2%, of whom 67.3% were prescribed atenolol (median dose 100 mg), and 25.0% were prescribed metoprolol (median dose 100 mg). Other beta-blockers used were sotalol (median dose 80 mg) and celiprolol (median dose 400 mg); 13.3% of patients were prescribed calcium channel blockers, 32.6% of whom were given nifedipine slow release (SR), at a median dose of 40 mg; 30.4% were given amlodipine (median dose 5 mg), 13.0% were given nicardipine (median dose 90 mg); 87% of patients were on dihydropyridine calcium channel blockers, all the others being on diltiazem (median dose 270 mg). However, of the patients taking dihydropyridines, 82.5% were on sustained release or longacting preparations. Forty per cent of patients were prescribed ACE inhibitors, 52.5% of whom were given lisinopril (median dose 5 mg), 18.2% were prescribed perindopril (median dose 4 mg), and 14.1% were prescribed enalapril (median dose The patient characteristics at the time of first monitoring for the four groups are shown in Table  1 . Age was broadly similar across the beta-blocker, calcium antagonist and ACEI groups, but was significantly higher in the diuretic group. This population also was alone in having a primarily female composition. This was felt to be consistent with a prescription bias in elderly populations toward diuretic therapy for isolated systolic hypertension, and a predominance of females in the more elderly patient population. Marginal differences were noted in body mass index, this variable being slightly lower in the diuretic group.
The heart rate and BP values on the first ABPM are presented in Table 2 . Blood pressure values were generally comparable across groups. The diurnal and nocturnal systolic BP was significantly lower in the beta-blocker group when compared with the calcium antagonist group. Heart rate during daytime, at night and in the initial period was similar.
The change in mean daytime and night-time BP from the first, unmedicated monitor to the second monitor on medicines is displayed in Table 3 , along with the calculated correlation coefficient and P value for association with the daytime mean heart rate on the first monitor. The closest association was for beta-blockers, where the degree of diurnal BP reduction from treatment was directly proportional to the mean daytime heart rate on the first ABPM (r = 0.26). A similar, albeit weaker association was also documented between diurnal mean heart rate and day (r = 0.13) and night-time (r = 0.14) BP response to ACE inhibition. No relationship was found for mean heart rate on the initial ABPM and BP response to calcium channel blockers or diuretics. The patient population was then grouped into patients with a mean DHR on the initial ABPM Ͻ75 bpm, and those with a DHR у75 bpm. These groups were then compared for response to antihypertensive treatment within the four drug classes, to determine whether there existed patient subgroups identifiable on the basis of resting mean daytime heart rate, who responded better to specific drug treatments. The data is summarised in Table  4 . Patients in the higher heart rate group responded better to beta-blockers than did those in the lower heart rate group, with respect to the fall in mean daytime BP. Similarly, a reduction in day and nighttime BP was observed in the ACE inhibitor group, with significantly greater falls in BP apparent in the higher heart rate group.
Discussion
The value of tailored drug therapy for management of disease is that the therapeutic regimen used will be efficient with respect to the cost, benefit and sideeffect profile of the agent used. The drugs used to treat hypertension are particularly pertinent here, as treatment is likely to last for a number of years, and compliance with medicines may be less than perfect. The choice of which agent to use is largely a matter of personal preference, in that most research 232 Table 3 Change in mean daytime (⌬Day MAP), and night-time (⌬Night MAP) mean arterial pressure between the first and second ABPM. Correlation coefficients (P value) for association between ⌬Day MAP and ⌬Night MAP associated for daytime heart rate (DHR), and night-time heart rate (NHR) on the first monitor. to date has concentrated on treatment of hypertension as a disease state, and identification of specific drug efficacy has not been extensively studied. This retrospective observational study examines whether heart rate, averaged over day and nighttime, can be used to predict the efficacy of antihypertensive drug therapy of a number of different drug groups. We have shown that for beta-blockers and ACE inhibitors, the degree of BP reduction consequent on treatment with these agents is related in a positive linear fashion to the mean day-time heart rate on the initial pre-treatment ABPM. The implication for practice, therefore, is that patients noted to have an elevated daytime heart rate on ABPM (Ͼ75 bpm) will benefit in particular from treatment with these agents. Furthermore, at lower heart rates (Ͻ75 bpm) these agents are less effective, and calcium channel blockers or diuretics may be preferable.
What pathophysiological correlates are there to explain this association? The most obvious is the influence of the sympathetic nervous system in the aetiology of hypertension. Abnormalities of the sympathetic nervous system have been well documented in patients with hypertension, 7, 8 and modification of sympathetic neural outflow can dramatically reduce BP in even severe hypertensives. 9 Elevated heart rate is a marker for sympathetic activity, 10 and, in studies of heart rate variability, 11 hypertensive patients have been found to have increased LF/HF (low frequency/high frequency) ratios, suggestive predominance of the sympathetic limb of the autonomic nervous system. It would follow therefore, that hypertension associated with a high mean heart rate would respond best to a sympatholytic anti-hypertensive medication.
For both the beta-blocker group and the ACE inhibitor group, the strongest correlation was found for daytime heart rate and degree of BP reduction. Night-time heart rate was not significantly associated with BP response to medicines. It is known that the heart rate slows during the night, and heart rate variability studies have documented a relative predominance of vagal (parasympathetic) activity at this time, with an abeyance of sympathetic input into heart rate control. 12 Therefore, the correlation between mean night-time heart rate and BP response to sympatholytics is unlikely to be close.
The finding of a modest correlation between heart rate and BP response to ACE inhibition might again be explained on the basis of the sympatho-inhibitory effect of ACE inhibitors in hypertensive populations. 13, 14 Angiotensin II receptors on pre-synaptic adrenergic nerve terminals modulate stimulated release of catecholamine neurotransmitters-ACE inhibition has therefore a 'beta-blocker' effect, which may in part explain our findings.
There is good reason to use a mid-70s level as the cut-off point for 'low' and 'high' heart rate. The mean population pulse rate from a variety of population studies lies between 70 and 80 bpm. 2 There is evidence from epidemiological studies 15 that the incidence of total and coronary heart mortality rises as heart rate rises above 75 bpm. Furthermore, the Framingham heart study shows an increase in coronary heart disease death for both men and women with heart rate greater than the 70s quintile. 16 The choice of 75 bpm has, therefore, clinical correlates with cardiovascular outcome.
The most significant drawback of this study is the fact that, as an observational study, it can only suggest associations, rather than objectively define con-crete relationships between variables. The actual mean differences in day-time BP-lowering effect of beta-blockers and ACE inhibitors between the low and high heart rate groups was not large, being 5.7 and 5.2 mm Hg respectively. These differences may be sufficient to reduce the total BP burden and so prevent end-organ complications.
In conclusion, we have shown that BP response to beta-blockers and ACE inhibitors is optimal in patients who show higher mean daytime heart rate on ABPM, and that at lower heart rates calcium channel blockers and diuretics may provide a better control of BP. Prospective trial data is required to further explore this relationship.
